Argenica Advances Stroke Trial and Secures FDA Orphan Status for ARG-006

• 80% patient dosing completed in Phase 2 ARG-007 acute ischaemic stroke trial
• FDA grants Orphan Drug and Rare Pediatric Disease designations for ARG-006
• Positive preclinical data supports ARG-007’s potential in Alzheimer’s and Parkinson’s diseases
• Cash reserves stand at $15.06 million after a cashflow positive quarter